1374342-38-7

Basic information

• Product Name: tert-butyl 4-[4-bromo-2-(difluoromethyl)phenyl]piperazine-1-carboxylate
• Synonyms: tert-butyl 4-[4-bromo-2-(difluoromethyl)phenyl]piperazine-1-carboxylate
• CAS NO: 1374342-38-7
• Molecular Weight: 391.256
• Mol File: 1374342-38-7.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-[4-bromo-2-(difluoromethyl)phenyl]piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-[4-bromo-2-(difluoromethyl)phenyl]piperazine-1-carboxylate(1374342-38-7)
• EPA Substance Registry System: tert-butyl 4-[4-bromo-2-(difluoromethyl)phenyl]piperazine-1-carboxylate(1374342-38-7)

Safety Data

• Hazardous Substances Data: 1374342-38-7(Hazardous Substances Data)

Upstream product

• 628326-05-6 4-(4-bromo-2-formylphenyl)piperazine-1-carboxylic acid tert-butyl ester 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1374342-39-8 tert-butyl-4-[2-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate 

Relevant articles and documents

BRAF DEGRADERS

Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.